Canada: CETA: Impact On Canada’s IP Regime


While the precise terms of the Canada-European Union Comprehensive Economic and Trade Agreement (CETA) have not yet been published, on October 29, 2013, the Government of Canada tabled a technical summary of the agreement-in-principle. The summary included details of how CETA would impact Canada's intellectual property regime. Among other things, CETA stands to impact protections for pharmaceuticals with respect to patent term, appeal rights and data protection, as well as for trade-marks with respect to counterfeit goods and EU Geographical Indications. The technical summary assumes that CETA will be ratified in 2015.

Pharmaceutical Patents

Patent Term Restoration

Patent Term Restoration (PTR) is available in many industrialized nations, but not Canada. PTR will provide additional incentives to innovate for those innovative pharmaceutical companies whose drug approvals are "delayed" during the Health Canada regulatory marketing approval process. In those cases, patent protections may not be adequate. In particular, delayed drug approval means that the patent covering a drug may expire around the same time that approval is granted by Health Canada. CETA aims to lessen the impact of this problem by granting up to two additional years of Canadian market exclusivity beyond the expiry of any patents.

Application of PTR will not be retroactive; pharmaceuticals that are already approved for sale in Canada will not receive any additional protection as a result of PTR.

This change will require, minimally, either an amendment to the Patent Act or an amendment to the Food and Drugs Act. The enacting provisions may be embodied in an amendment to either act or, more likely, by Regulations made pursuant to the amendment. In the latter case, an amendment to either the Patent Act or the Food and Drugs Act will grant the regulation-making power necessary to create Patent Term Restoration Regulations.

Appeal Rights and Duplicative Litigation under the PM(NOC) Regulations

At present, within days of an innovator losing an Application under the Patented Medicines (Notice of Compliance) Regulations ("PM(NOC) Application") the generic is granted a Notice of Compliance, i.e., official approval to sell a drug in Canada. Canadian Courts have held that this renders any appeal by the innovative company moot. In short, the innovator may not appeal if it loses a PM(NOC) Application.

On the other hand, should the generic lose a PM(NOC) Application, the generic may appeal that decision to the Federal Court of Appeal and potentially even to the Supreme Court of Canada (for instance, Teva v. Pfizer (Viagra), 2012 SCC 60). CETA strives to introduce balance and fairness to the PM(NOC) Application process by granting the innovator a right of appeal, as similarly granted to the generic.

Currently, if the innovator loses a PM(NOC) Application, the usual course is to launch an action for patent infringement once the generic comes to market. Similarly, if the generic loses during the PM(NOC) Application process, it is open to the generic to initiate an action to impeach any pertinent patents. Both of these  actions proceed under the Patent Act.

The PM(NOC) Regulations currently prescribe a 24-month window during which the entire PM(NOC) Application must take place; after 24 months from the date the Application starts the generic will be issued a NOC. In the case of an appeal by the generic, the Federal Court will have decided that a NOC should not issue. Thus, the 24-month period is not implicated. However, any appeal by the innovator will almost certainly exceed the 24-month window. How CETA will address this issue is currently unknown.

For innovators appealing a PM(NOC) Application decision, the Federal Court will have decided that a NOC should issue to the generic. Another open question is whether the generic's NOC will be held in abeyance pursuant to a stay pending the outcome on appeal or, whether the generic's NOC will be revoked should the innovator succeed on appeal.

A stated goal of CETA is to prevent duplicative litigation, such as a PM(NOC) Application followed by a Patent Act action. While the final form of CETA is unknown, one possible way of preventing duplicative litigation is to require the loser at the PM(NOC) Application stage to elect either an appeal from the PM(NOC) Application or an action under the Patent Act for infringement (or impeachment). In that case, if the innovator loses the PM(NOC) Application, the innovator must elect between appealing that decision and the right to sue for infringement once the generic comes to market. It follows that if the generic loses the PM(NOC) Application, it too must elect between appealing that decision and bringing an action to impeach the relevant patents in rem.  Otherwise, the goal of preventing duplicative may not be achieved.

Another option would be for Canada to follow the U.S.'s lead and require a full action on the merits in lieu of a PM(NOC) Application as a condition for generic market approval. This would require the generic to commence an action to impeach the relevant patents in advance of being issued a NOC. This may require longer than the currently-prescribed 24-months.

These changes will require an amendment to the Patented Medicines (Notice of Compliance) Regulations. Since these regulations were enacted pursuant to a regulation-making power set out in s 55.2 of the Patent Act, no amendment to the Patent Act will likely be required.

Data Protection

CETA will enshrine Canada's current term of data protection (i.e., 6 years before a generic can file an Abbreviated New Drug Submission if it relies on the innovator's data, and 8/8.5 years before issuance of a Notice of Compliance to the generic).

The commitment to providing 8 years of data protection does not differ from current Canadian law. Thus, no changes are required to the Data Protection Regulations (DPR). However, CETA will prevent any amendments to the DPR that would decrease the term of protection to less than 8 years.


Treaty Compliance

The trade-mark profession had speculated that CETA might require Canada to accede to the Madrid Protocol. However, in light of the technical summary released by the Government of Canada, this requirement does not appear to be part of CETA. In fact, Canada will not be required under CETA to take on any specific trade-mark treaty commitments. Rather, Canada has instead agreed to make "best endeavours" and "all reasonable efforts" to ensure compliance with international trade-mark agreements and standards (including the Singapore Treaty on the Law of Trademarks, and the Madrid Protocol). These "endeavours" have the goal of "encourag[ing] more effective trade-mark procedures".  

Counterfeit Goods

CETA will also include several commitments aimed at curtailing trade in counterfeit goods. Civil remedies and border enforcement rights will likely form much of Canada's obligations. These are already in line with Canada's anti-counterfeiting regime, and are in keeping with the proposals found in pending Bill C-8, the Combating Counterfeit Products Act, introduced to Canadian Parliament on October 28, 2013.

Bill C-8 has passed second reading, and is now before a Committee for review.  While this is an encouraging development in the fight against the counterfeit trade, concerns exist that further amendments to Bill C-8 may be required to enhance the effectiveness of Canada's anti-counterfeiting and anti-piracy regime as it relates to border enforcement, resource allocation, and the bearing of costs related to storage, handling and destruction of counterfeit goods.   Additionally, the offences, punishment and remedy provisions may need further revisions if brand owners are to rely on these provisions to enforce their rights in a pragmatic and meaningful manner.

Geographical Indications (GIs)

Under CETA, Canada will provide protection for 179 terms covering various foods and beer, in addition to those EU wines and spirits GIs currently recognized by Canada. The nature and scope of protection will vary depending upon the specific GI in question. Protection will not prejudice any existing Canadian trade-mark holders and will not impact customary names for plant and animal breeds.

CETA preserves the right to use common English and French names for food products.  For example, Canadian producers would be able to use English and French but not the German language for Black Forest ham. Terms that continue to be free for use in Canada include Valencia orange, Black Forest ham, Tiroler bacon, Parmesan, Bavarian beer, and Munich beer.

CETA also limits the GI rights provided to EU with respect to Asiago, feta, fontina, Gorgonzola and Munster. While current users are unaffected, future users will be able to use the names only when accompanied by expressions such as "kind," "type," style," "imitation" or the like.

CETA also allows Canada to maintain the ability to use components of multi-part terms. For example: "Brie de Meaux" will be protected, but the term "brie" can be used on its own;         "Edam Holland" will be protected, but the term "Edam" can be used on its own.

Ultimately, according to the technical summary of CETA, enforcement of GIs in Canada is expected to remain a private matter to be determined by the Courts. Commitments as to border enforcement of GIs are to be confirmed at a later date.


It appears that Canada's copyright regime is compliant with CETA. The Recent Copyright Modernization Act effected significant amendments to the prior version of the Copyright Act and brought Canada into compliance with the 1996 World Intellectual Property Organization treaties: Copyright, and Performances and Phonograms.

Additionally, certain provisions regarding the term of protection, broadcasting, and others have been enshrined in CETA. As a result, no amendments to the Copyright Act are anticipated.


According to the technical summary of CETA, Canada's existing legal regime is compliant with CETA.  For example, CETA will not change the "farmers' privilege" to save and replant seeds of a protected variety on their own land under the federal Plant Breeders' Rights' Act.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
8 Nov 2016, Seminar, Ottawa, Canada

The prospect of an internal investigation raises many thorny issues. This presentation will canvass some of the potential triggering events, and discuss how to structure an investigation, retain forensic assistance and manage the inevitable ethical issues that will arise.

22 Nov 2016, Seminar, Ottawa, Canada

From the boardroom to the shop floor, effective organizations recognize the value of having a diverse workplace. This presentation will explore effective strategies to promote diversity, defeat bias and encourage a broader community outlook.

7 Dec 2016, Seminar, Ottawa, Canada

Staying local but going global presents its challenges. Gowling WLG lawyers offer an international roundtable on doing business in the U.K., France, Germany, China and Russia. This three-hour session will videoconference in lawyers from around the world to discuss business and intellectual property hurdles.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.